Diabetes Therapeutics Market to Reach US$321.96 Billion by 2033 as Massive Patient Base, Recurring Treatment Demand and Next-Generation Drug Classes Transform Chronic Disease Care

NEW YORK, May 24, 2026 - According to DataM Intelligence, the global Diabetes Therapeutics Market reached US$76.75 billion in 2023, increased to US$89.46 billion in 2024 and is expected to reach US$321.96 billion by 2033, growing at a CAGR of 15.4% during 2025 to 2033. The market is segmented by type into type 1 diabetes, type 2 diabetes and gestational diabetes, by drug class into insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors and others, and by route of administration into injectable and oral therapies.

The global diabetes therapeutics market is entering a high-value expansion cycle as diabetes becomes one of the most persistent and costly chronic diseases worldwide. On a growth-multiple basis, the market is expected to expand approximately 3.60x by 2033, reflecting the long-term commercial strength of a therapy area supported by continuous patient demand, lifelong medication use and rapid innovation in advanced drug classes.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/diabetes-therapeutics-market?kailas

Why Diabetes Therapeutics Is a Highly Sellable Market

Diabetes therapeutics is highly sellable because diabetes has a massive global patient base and recurring treatment demand. Unlike acute care categories where treatment may be short-term, diabetes requires ongoing management through oral drugs, insulin, injectable therapies, lifestyle intervention, glucose monitoring and complication prevention. This creates a durable treatment market where demand is driven not only by new diagnoses but also by long-term therapy continuation, dose escalation, combination regimens and switching to newer drug classes.

The scale of the disease burden is one of the strongest commercial signals. WHO reported that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022, while more than half of people living with diabetes were not taking medication for diabetes in 2022. This treatment gap points to significant unmet need and long-term access expansion potential.

A Chronic Disease Market Built on Recurring Therapy Demand

The diabetes therapeutics market is commercially resilient because treatment is rarely one-time. Patients may begin with basic oral antidiabetic drugs and later require combination therapies, injectable drugs, insulin, GLP-1 receptor agonists or SGLT-2 inhibitors depending on disease progression, weight, cardiovascular risk, kidney function and glycemic control. DataM Intelligence notes that traditional therapies such as insulin and metformin are increasingly being complemented by newer drug classes including GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors and dual or triple agonists.

This recurring demand profile makes diabetes therapeutics one of the most dependable pharmaceutical markets. Type 1 diabetes requires lifelong insulin therapy, while type 2 diabetes often progresses over time and can require additional drug classes or insulin intensification. Gestational diabetes adds another demand pathway linked to pregnancy-related care. Together, these patient groups create a broad and continuous treatment ecosystem across hospital pharmacies, retail pharmacies and online pharmacies.

Patient Base Expansion Strengthens the Market's Long-Term Value

The long-term patient pool is expanding rapidly. DataM Intelligence cites International Diabetes Federation projections that by 2050, approximately 853 million adults will have diabetes, representing a 46% increase, with more than 90% of cases being type 2 diabetes. IDF's 2025 Atlas also reports that 1 in 9 adults aged 20 to 79 is living with diabetes, and more than 4 in 10 adults with diabetes are unaware they have the condition.

This matters because undiagnosed and undertreated diabetes represents future treatment demand. As screening improves, healthcare access expands and awareness rises, more patients are expected to enter therapy. In emerging markets, rising urbanization, aging populations, lower physical activity and changing diets are increasing type 2 diabetes prevalence, creating large-volume demand for affordable generics, biosimilars, oral drugs and next-generation therapies.

Insulin Remains the Core Revenue Anchor with 69.06% Market Share

Insulin remains the foundation of the diabetes therapeutics market. DataM Intelligence states that the insulin drug class is expected to hold 69.06% of the diabetes therapeutics market, supported by rising diabetes prevalence, rapid-acting and long-acting insulin innovation, biosimilar insulin availability, smart delivery devices and integration with continuous glucose monitoring.

The insulin segment continues to evolve through delivery innovation. Insulin pens, pumps, smart connected devices and continuous glucose monitoring integration are making insulin therapy more precise and convenient. DataM Intelligence also highlights Cipla's December 2024 approval from India's Central Drugs Standard Control Organization to market and distribute Afrezza, an inhalable insulin developed by MannKind Corporation, offering a needle-free option for adults with type 1 and type 2 diabetes.

GLP-1 and SGLT-2 Therapies Expand the Market Beyond Glucose Control

The diabetes therapeutics market is becoming more attractive because newer drug classes offer benefits beyond glucose lowering. DataM Intelligence notes that GLP-1 receptor agonists and SGLT-2 inhibitors are gaining preference because they can support weight loss and cardiovascular protection, making them increasingly important in treatment decisions.

This shift is transforming diabetes care from glucose-centric management into broader cardiometabolic treatment. GLP-1 therapies are especially powerful because they connect diabetes care with obesity management and weight-loss demand. SGLT-2 inhibitors are also important because of their relevance in cardiovascular and kidney-related risk management. These benefits increase treatment value, strengthen premium pricing potential and support broader adoption among patients with complex metabolic risk profiles.

Digital Diabetes Care Creates a New Growth Layer

Digital health is becoming a major opportunity in diabetes therapeutics. DataM Intelligence identifies continuous glucose monitors, smart insulin pens, mobile health applications, telemedicine platforms and AI-driven decision support tools as important technologies improving real-time glucose tracking, treatment adherence, patient engagement and personalized therapy adjustment.

This digital layer strengthens the market because diabetes management depends on daily behavior, medication adherence and frequent monitoring. Connected devices and mobile platforms can help patients track glucose, receive medication reminders, monitor diet and communicate with healthcare providers. As diabetes care becomes more integrated, therapeutics are increasingly linked with monitoring devices, digital platforms and personalized care models.

North America Leads, Asia Pacific Becomes a High-Growth Volume Market

North America leads the global diabetes therapeutics market due to advanced healthcare infrastructure, high disease prevalence, strong reimbursement structures, high healthcare spending and active research and development. DataM Intelligence states that North America's diabetes therapeutics market was expected to reach US$37.66 billion in 2024, supported by access to advanced therapies such as next-generation insulin analogues, GLP-1 receptor agonists and digital diabetes care tools.

Asia Pacific is becoming one of the most important growth regions because of rapid urbanization, changing dietary habits, reduced physical activity, rising type 2 diabetes prevalence and expanding healthcare access. DataM Intelligence reports that the Asia Pacific diabetes therapeutics market was expected to reach US$21.06 billion in 2024, supported by demand from countries such as India and China, public health campaigns, screening programs, cost-effective biosimilars and generics, and a growing middle-class population.

Cost Burden Reinforces the Need for Accessible Therapies

The high cost of diabetes care remains a major restraint but also confirms the size of the economic burden. DataM Intelligence cites the estimated cost of diagnosed diabetes in the U.S. at US$412.9 billion in 2022, including US$306.6 billion in direct medical costs and US$106.3 billion in indirect costs.

This cost pressure is driving demand for more accessible treatment options, including biosimilar insulins, generics, fixed-dose combinations and patient-friendly delivery systems. While advanced therapies such as GLP-1 receptor agonists and insulin analogues can be expensive, the long-term cost of uncontrolled diabetes is also substantial due to complications such as cardiovascular disease, kidney failure, neuropathy and other chronic conditions.

Key Developments Show Strong Innovation Momentum

Recent developments demonstrate the pace of market innovation. In June 2025, Eli Lilly announced Mounjaro in KwikPen for the Indian market, a single-patient-use prefilled pen designed for once-weekly administration in adults with type 2 diabetes. DataM Intelligence also highlights Vertex Pharmaceuticals' progress in type 1 diabetes, including completion of enrollment and dosing for Parts A and B of its Phase 1/2 study of VX-264, an investigational therapy combining fully differentiated pancreatic islet cells with an immunoprotective device.

Cell-based therapies, needle-free insulin, smart delivery systems and dual or triple agonists show that the market is not limited to traditional diabetes drugs. It is moving toward more convenient, personalized and integrated treatment models. This innovation pipeline increases the report's commercial appeal because buyers need continuous intelligence on product development, regulatory movement, launch timing, competitive positioning and regional adoption.

Competitive Landscape: Global Leaders Compete Across Insulin, GLP-1, SGLT-2 and Digital Care

The global diabetes therapeutics market includes major players such as Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim, Johnson & Johnson through Janssen, Novartis AG, Biocon Limited and Innogen Biopharmaceuticals. These companies compete across insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, biosimilars, oral therapies, injectable therapies and integrated diabetes care models.

Competition is expected to intensify around long-acting formulations, biosimilar insulin, oral versions of injectable drugs, fixed-dose combinations, cardiometabolic benefits, weight-loss positioning, smart insulin delivery and digital treatment integration. Companies that can balance efficacy, convenience, affordability and access are likely to gain stronger visibility as diabetes care expands across both developed and emerging markets.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diabetes-therapeutics-market?kailas

Strategic Outlook: Diabetes Therapeutics Becomes a Defining Chronic Care Market Through 2033

The diabetes therapeutics market is positioned for sustained expansion because it combines a massive patient base, recurring treatment demand, rising diagnosis rates, long-term medication use and continuous therapeutic innovation. The projected rise from US$89.46 billion in 2024 to US$321.96 billion by 2033 shows that diabetes therapeutics will remain one of the largest and most commercially durable pharmaceutical markets globally.

The next phase of market growth will be shaped by GLP-1 adoption, insulin innovation, SGLT-2 expansion, biosimilar access, oral therapy development, smart insulin pens, continuous glucose monitoring, mobile health platforms and AI-powered diabetes management. Because diabetes requires continuous care and long-term treatment, this market offers a rare combination of scale, repeat demand, clinical urgency and innovation-led growth.

About the Report

The Diabetes Therapeutics Market report by DataM Intelligence analyzes the market by type, drug class, route of administration, distribution channel and region. Type coverage includes type 1 diabetes, type 2 diabetes and gestational diabetes. Drug class coverage includes insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors and others. Distribution channel coverage includes hospital pharmacies, retail pharmacies and online pharmacies across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.